Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 2015. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibilities (PDMRs), or connected persons, in accordance with DTR 3.1.4R(1)(a).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure regarding specific share transactions rather than a financial performance report.
Material Changes
The filing discloses an increase in the actual interests of Mr. W C Louv, a Person Discharging Managerial Responsibility. The change resulted from the re-investment of dividends paid on American Depositary Shares (ADSs) held in the vested portion of the GSK 2009 Deferred Annual Bonus Plan Post-Tax awards.
- Transaction Date: July 24, 2015
- Price per ADS: $42.36
- ADSs Acquired: 35.491
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the notification of the specific PDMR transaction described above.
Investor Verification Points
- Verify the total shareholding of Mr. W C Louv following this transaction to assess concentration of interest.
- Confirm the terms of the GSK 2009 Deferred Annual Bonus Plan Post-Tax awards to understand the mechanism of the dividend re-investment.
- Review the market price of GSK ADSs on July 24, 2015, to validate the reported transaction price of $42.36.